MedPath
FDA Approval

Kitabis Pak

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 10, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Tobramycin(300 mg in 5 mL)

Manufacturing Establishments3

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Chongqing Daxin Pharmaceutical Co. Ltd.

Pari Respiratory Equipment, Inc.

421297606

Woodstock Sterile Solutions, Inc.

Pari Respiratory Equipment, Inc.

117895702

Catalent Pharma Solutions

Pari Respiratory Equipment, Inc.

014167995

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Kitabis Pak

Product Details

NDC Product Code
24492-850
Application Number
NDA205433
Marketing Category
NDA (C73594)
Route of Administration
RESPIRATORY (INHALATION)
Effective Date
November 30, 2019
Code: VZ8RRZ51VKClass: ACTIBQuantity: 300 mg in 5 mL
Sulfuric AcidInactive
Code: O40UQP6WCFClass: IACT
Sodium ChlorideInactive
Code: 451W47IQ8XClass: IACT
WaterInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath